227 related articles for article (PubMed ID: 34815180)
1. Linking liver metabolic and vascular disease via bile acid signaling.
Fiorucci S; Distrutti E
Trends Mol Med; 2022 Jan; 28(1):51-66. PubMed ID: 34815180
[TBL] [Abstract][Full Text] [Related]
2. Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling.
Ren ZL; Li CX; Ma CY; Chen D; Chen JH; Xu WX; Chen CA; Cheng FF; Wang XQ
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361829
[TBL] [Abstract][Full Text] [Related]
3. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
[TBL] [Abstract][Full Text] [Related]
5. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
[TBL] [Abstract][Full Text] [Related]
6. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
Marchianò S; Biagioli M; Morretta E; Di Giorgio C; Roselli R; Bordoni M; Bellini R; Urbani G; Massa C; Monti MC; Zampella A; Distrutti E; Fiorucci S
Sci Rep; 2023 Jan; 13(1):1602. PubMed ID: 36709356
[TBL] [Abstract][Full Text] [Related]
8. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Urbani G; Morretta E; Monti MC; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159218. PubMed ID: 35985473
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
[TBL] [Abstract][Full Text] [Related]
11. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
[TBL] [Abstract][Full Text] [Related]
12. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
[TBL] [Abstract][Full Text] [Related]
13. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
14. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease.
Wang C; Zhu C; Shao L; Ye J; Shen Y; Ren Y
Mediators Inflamm; 2019; 2019():7659509. PubMed ID: 31341422
[TBL] [Abstract][Full Text] [Related]
15. Bile acids are nutrient signaling hormones.
Zhou H; Hylemon PB
Steroids; 2014 Aug; 86():62-8. PubMed ID: 24819989
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
17. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
18. The role of bile acids in regulating glucose and lipid metabolism.
Yu H; Nie R; Shen C
Endocr J; 2023 Apr; 70(4):359-374. PubMed ID: 36928060
[TBL] [Abstract][Full Text] [Related]
19. Deoxyschizandrin ameliorates obesity and non-alcoholic fatty liver disease: Involvement of dual Farnesyl X receptor/G protein-coupled bile acid receptor 1 activation and leptin sensitization.
Gu M; Feng Y; Chen Y; Fan S; Huang C
Phytother Res; 2023 Jul; 37(7):2771-2786. PubMed ID: 36809683
[TBL] [Abstract][Full Text] [Related]
20. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
Wang S; Sheng F; Zou L; Xiao J; Li P
J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]